ABSTRACT
INTRODUCTION

Guillain-Barré syndrome (GBS) is a post-infectious polyradiculoneuropathy with variable
clinical and electrophysiological subtypes. GBS is commonly subdivided into acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and acute motor sensory axonal neuropathy (AMSAN). There is a remarkable difference in geographical distribution of these subtypes.
[1] The axonal variants abound in Asia, while AIDP is predominant in western countries. [1] [2] [3] This geographical variation is unexplained, but may be related to differences in genetic or environmental factors. Previous studies indicated that preceding infections may influence the electrophysiological subtype of GBS. [4] [5] [6] More specifically, a recent study proposed that in Japan infections with
Campylobacter jejuni are exclusively related to AMAN. [7] The high incidence of C. jejuni infections in GBS patients in Japan would explain why axonal variants predominate there.
Patients from western countries most frequently report symptoms of preceding respiratory tract infections. Indeed, serological studies have yielded evidence for infections with cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Mycoplasma pneumoniae. (5) Nevertheless, in these regions C. jejuni is the predominant type of infection preceding GBS, that may affect >30% of patients. [8, 9] AMAN in western countries is rare (<10%), [3, 10] however, suggesting that C. jejuni in western patients may also induce other GBS subtypes.
Here, we defined what subtypes of GBS may occur after C. jejuni infection in the Netherlands. C. jejuni infections were defined by specific techniques, including those used in Japanese studies, to exclude methodological bias. Patients with C. jejuni infections were assessed in serial electrophysiological studies and compared with patients with preceding viral infections.
PATIENTS AND METHODS
Patients
The patients for our study were derived from a cohort of 147 GBS patients who participated in a randomised trial comparing the therapeutic effect of intravenous immunoglobulins (IVIg) versus plasmapheresis. [11] All patients fulfilled the diagnostic criteria for GBS, were admitted to the hospital within two weeks of onset of weakness, and were unable to walk ten meters independently (GBS disability score > 2). [12] During a follow-up of six months, the patients underwent neurological assessments at standardised time points according to a predefined protocol. During these visits, clinical parameters such as sensory abnormalities, cranial nerve involvement, GBS disability scales, and MRC sum scores were determined. [13, 14] Informed consent was obtained from all patients and the study was approved by the local medical ethics committee. Data from serial electrophysiological studies and pretreatment serum samples were available from 123 (84%) of the 147 patients. These patients were not significantly different from the excluded 24 cases regarding baseline and clinical characteristics.
To confirm our findings in patients with positive C. jejuni serology in this cohort, we analysed patients with positive C. jejuni stool cultures from a second cohort who participated in a trial studying the effect of combined IVIg and methylprednisolone treatment. [15] For this later cohort, stool specimens were available, allowing isolation of C. jejuni bacteria directly from these specimens (the gold standard for identification of a recent C. jejuni infection). In this second cohort, eight (4%) of 225 GBS patients were identified with a positive stool culture for C. jejuni. All eight patients of this second cohort fulfilled the diagnostic criteria for GBS, underwent an extensive follow-up, and had an EMG within three weeks after randomisation. [15] Electrophysiology Electrophysiological findings vary considerably in the acute stage of GBS. This dynamic situation may lead to changes in classification of patients depending on the timing of the EMG. Therefore, in this study, serial EMG studies were performed at three standard time points: within two days of hospital admission, after one week, and after one month. [10] Kuwabara et al. categorized their EMGs based on the time elapsed since the onset of weakness rather than the time of admission. [7] To be able to compare our study with this previous study, we chose to analyse the EMGs that were made in the second week after onset of weakness (median 11 days, 95% CI 10-12 days) and more than 4 weeks after onset of weakness (median 33 days, 95% CI 32-38 days).
Motor and sensory nerve conduction studies were performed on the ulnar and median nerves.
Stimulation and recordings were performed at standardised sites. [16, 17] Recordings from motor nerves were quantified using peak-to-peak distal and proximal compound motor action potential amplitudes (dCMAP and pCMAP), distal motor latency (DML), motor nerve conduction velocity (mNCV), and F-wave latencies. For sensory nerves, the peak-to-peak sensory nerve action potential (SNAP) amplitude and sensory nerve conduction velocity (sNCV) were measured. Needle EMG was performed in the anterior tibial muscle, abductor pollicis brevis muscle or the abductor digiti minimi muscle to determine the presence of denervation activity (fibrillation potentials and positive sharp waves). In all investigations, the electromyographers were blinded for the results of infection serology. The EMGs were classified as demyelinating, axonal, inexcitable, equivocal, or normal according to the Hadden criteria. Reference values were defined previously. [17] The temperature of the recording-and stimulation sites were registered.
Serological studies
Pre-treatment serum samples were examined for evidence of a recent C. jejuni infection using tests from both Japanese and Dutch laboratories (Dokkyo Medical University in Tochigi, Japan, and SSDZ, Delft, The Netherlands). [18, 19] Both tests were based on an ELISA, and have been described in detail previously. [20, 21] In the Japanese laboratory, serological evidence of a recent C. jejuni infection was defined as anti-C. jejuni IgG titres of 2,000 or more; in the Dutch laboratory as the presence of anti-C. jejuni IgM or IgA antibodies at higher levels than an internal standard. [8] Differences between the Japanese and Dutch tests were described previously. [19] Both tests were used in the current study to exclude the possibility that the serology method introduced a bias. Patients were regarded C. jejuni-positive if they:
(1) suffered from diarrhea in the three weeks preceding the onset of weakness, and (2) were tested positive for C. jejuni serology in either one of the two independent laboratories. The C.
jejuni-related patients were compared with a group of GBS patients from the same trial cohort who had a positive serology for a recent infection with CMV or EBV according to previously defined criteria. [8] Furthermore, the pretreatment serum samples were tested for IgM and IgG antibody reactivity against GM1 and GD1a (in The Netherlands), and against GM1, GM1b, and GalNAc-GD1a (in Japan) using ELISA as previously described. [22, 23] 
Statistical analysis
Normally distributed data were analysed using the two-sided t-test for independent samples.
Ordinal data and not normally distributed data were analysed using the two-sided Wilcoxon rank sum score test. The χ 2 test or Fisher exact test was used for categorical data depending on sample size. Data are presented as means and standard deviations (SD) or as medians and 95% confidence intervals (95% CI). For categorical variables, frequencies and percentages are
given. All calculations were performed using SPSS 15.0 (SPSS Inc, Chicago, IL). A p-value of < 0.05 was considered to be statistically significant.
RESULTS
Comparison of patients with C. jejuni-versus CMV/EBV-related GBS
The electrophysiology of the patients with positive C. jejuni serology was compared with that of patients with a positive CMV or EBV serology. Seventeen (14%) of the cohort of 123 GBS patients met our strict criteria for a recent infection with C. jejuni (diarrhea and positive C.
jejuni serology). In the same cohort of patients 24 (20%) had a positive serology for either CMV or EBV. The electrophysiological characteristics of the CMV-and EBV-related patients were very similar; therefore, both groups were combined for further analysis. The mean age of the C. jejuni-related patients (56 ± 17 years) was significantly higher than of the CMV/EBV-related patients (36 ± 15years) (p < 0.001). Sensory deficits were less frequent in the C. jejuni-related patients (41%) compared to the CMV/EBV-related patients (78%) (p = 0.02). The median MRC sum score after six months was lower in the C. jejuni-related patients (44 with 95% CI 31-58) than in the CMV/EBV-related patients (58 with 95% CI 52-60) (p = 0.004). The median GBS disability score at six months was significantly higher for the C.
jejuni-related patients (3 with 95% CI 1-4) compared to the CMV/EBV-related patients (1 with 95% CI 1-2) (p = 0.02), indicating a poorer outcome. Anti-ganglioside antibodies were present in 88% of the C. jejuni-related patients and in 4% of the CMV/EBV-related patients (p < 0.001).
The two groups differed considerably with respect to electrophysiological features and subtypes, as shown in Table 1 . The C. jejuni-related patients had significantly lower CMAP amplitudes and lower DMLs, but higher SNAP amplitudes. These differences were found in both the ulnar and median nerves, although the differences in the ulnar nerves were more pronounced.
The frequency of denervation activity (fibrillation potentials and/or positive sharp waves) in the acute phase and at 4 weeks did not differ significantly between the two groups. Within 2 weeks, 20% of the C. jejuni patients and 21% of the CMV/EBV patients showed denervation activity (p=0.95). After 4 weeks, 69% of the C. jejuni patients versus 56% of the CMV/EBV patients showed active denervation (p=0.44).
In five patients from the CMV/EBV-related group, an EMG was performed only within two weeks and not after four weeks. At four weeks, the majority of EMGs in the C. jejuni-related group were classified as the axonal type or as inexcitable, but two patients (12%) had a demyelinating type of EMG. By contrast, at that time 85% of the EMGs of the CMV/EBVrelated patients were classified as demyelinating.
The distal temperature during all EMG registrations was not decreased, except for two These two subgroups were indistinguishable in terms of clinical and electrophysiological characteristics and, therefore, were combined for further analysis. Table 2 provides an overview of the electrophysiological and serological data for all C. jejuni-serology positive patients.
Three of these 17 patients with positive C. jejuni serology fulfilled the electrophysiological criteria of Hadden for demyelination at one or both time points (Table 3) . Four weeks after the onset of weakness, when most patients have reached a stable situation, two of these three patients fulfilled the criteria for demyelination. The first patient (study number 6) also had high titers of IgG antibodies to GM1 in the Japanese and Dutch assays, normal SNAPs, and a purely motor form of GBS. Needle EMG did not show any signs of axonal damage in the form of fibrillation potentials and/or positive sharp waves. The second patient (study number 15) had high titers of IgG antibodies to GM1 in the Dutch assay and of GM1, GM1b and GalNAc-GD1a in the Japanese assay. This patient had abnormal SNAPs. Needle EMG also showed signs of axonal involvement (fibrillation and positive sharp waves). The third patient (study number 16), tested negative for anti-ganglioside antibodies, had abnormal SNAPs, and no denervation potentials in needle EMG.
Classification of patients with positive C. jejuni-stool culture
Two (25%) of the eight patients from the second cohort with a stool sample that was positive for C. jejuni fulfilled the demyelination criteria (Table 3) . Patient A was a 63-year-old male who was admitted with a progressive burning sensation and paresthesias in hands and feet and, one day later, progressive muscle weakness. His EMG was performed 19 days after weakness onset and showed prolonged DMLs in combination with low NCVs, a conduction block, and absent SNAPs. Needle EMG showed no denervation activity. He had a positive serology for IgG anti-GM1 antibodies. Patient B was a 36-year-old female, with pronounced muscle weakness and mild sensory disturbance. Her EMG was performed 12 days after weakness onset and showed prolonged DMLs in median, ulnar and peroneal nerve, an abnormal mNCV in the median nerve, and abnormal SNAPs of median and ulnar nerve.
Needle EMG showed no denervation activity. No serum antibodies to gangliosides were found. Inexcitable: dCMAP absent in all nerves (or present in 1 nerve with dCAMP<10% LLN).
Equivocal: does not fit criteria for any other group. To be able to clarify which GBS subtypes can be elicited by a C. jejuni infection, our first priority was to prevent the inclusion of false-positive C. jejuni cases. For that reason, an extensively validated serological assay was used, which has a sensitivity of 96% and a specificity of 93% for detecting a recent C. jejuni infection in patients with GBS. [18] To further increase the specificity, we added the criterium of presence of preceding diarrhea. This combination of strict criteria explains the low frequency of C. jejuni-related cases compared to previous studies. [5, 22, 24] The specificity of the C. jejuni serology may differ among assays. [2, 19] To make our results as comparable as possible to previous studies from Japan, [7] serological testing for C. jejuni was performed in the Netherlands as well as in Japan. The findings that anti-ganglioside antibodies were almost exclusively found in the patients with positive C. jejuni serology, lend further support to a high specificity of the assays. Furthermore, in two GBS patients with a positive stool culture for C. jejuni, the gold standard for identifying a recent infection, demyelinating forms were identified. Taken together, it is highly unlikely that the observed coincidence of C. jejuni infection and AIDP in five out of the total 25 C. jejuni-positive patients can be explained by false-positive cases of
C. jejuni.
The second issue that needs to be addressed in this context is whether the electrophysiological features observed in these five patients can be attributed rightly to the process of demyelination. In the current study we have used the criteria of Hadden et al. [3] These criteria were developed in Caucasian GBS patients, but are similar to the criteria of Ho et al., [2] that were used in the previous study from Japan. [7] All patients in the current study that were classified as AIDP with the Hadden's criteria, including the two C. jejuni-culture positive patients, also fulfilled these criteria for AIDP of Ho et al. Over the years, multiple sets of electrophysiological (research) criteria have been developed to identify demyelination in GBS patients. [2, 3, 10, [25] [26] [27] No set is universally accepted, however, and no comparative studies with nerve biopsies are available for GBS including the current study. Furthermore, a few studies have shown the existence of conduction blocks, conduction slowing, and increased DMLs in AMAN patients. [28, 29] These phenomena were presumably caused by alteration of the resting membrane potential and sodium channel inactivation. Along the same lines, it should be noted that three of the five C. jejuni-positive patients with AIDP in our study had high titres of serum IgG antibodies to GM1 or other gangliosides. Only one of these patients also had signs of axonal involvement in the form of fibrillation potentials and positive sharp waves on EMG. Usually, these antibodies are strongly associated with axonal degeneration. [22, 30] Possibly, these findings point to the existence of an as yet unrecognized subtype, which merges axonal and demyelinating characteristics on EMG. Within the limits of the currently available criteria (whether those of Hadden, Ho or others), however, the EMGs of the five patients unmistakably show primary demyelinating features. Moreover, the majority had marked sensory abnormalities on the EMG, which are very uncommon in AMAN. [29] The current study is based on the EMGs of median and ulnar nerves, the only two motor nerves that were studied in this patient cohort systematically. In the study of Kuwabara et al, four motor nerves were examined. [7] . The current criteria require the presence of a demyelinating feature in at least two nerves, which enabled us to classify patients with AIDP.
Performing EMG in a third (or fourth) nerve will only increase the sensitivity to detect demyelination.
A third potential confounder for the subtyping of GBS patients is the timing of the EMG, since the electrophysiological findings vary considerably in the acute stage of GBS. [26] This dynamic situation may lead to changes in the classification of patients during follow-up, as was found in our study as well as that of Japan. [7] Four weeks after weakness onset, the situation may be expected to have stabilized. Even at that time, some of our patients fulfilled the electrophysiological criteria for demyelination. In this context, it should also be noted that none of our C. jejuni patients with a demyelinating EMG had the previously reported quickly reversible conduction blocks and increased DMLs that normalize within two weeks after weakness onset. [7] More extensive studies are required to establish the relations between the geographical and ethnical origin of the patient, the type of preceding infections, and the subsequent electrophysiological and clinical phenotype. If the patient's origin indeed influences the phenotype of GBS after infection with C. jejuni, this raises the question which factors could explain such an association. Previous studies showed that the type of C. jejuni strain and related ganglioside mimicry or additional virulence factors highly influence the subsequent neurological deficits. [31] Possibly, these characteristics vary between C. jejuni strains derived from different geographical areas. In addition to these pathogen factors, host factors may codetermine the phenotype by influencing the specificity and type of immune response triggered by a preceding C. jejuni infection. Alternatively, the antigenic make-up of the peripheral nervous system or accessibility of these targets to the immune system may depend on the origin of the host. Various genetic factors are associated with disease occurrence and severity. [32] [33] [34] Extensive international collaboration and comparisons of large and standardized cohorts of GBS patients from various geographical and ethnical origins are required to resolve these issues. In addition, the current classification into demyelinating and axonal subtypes based on EMG characteristics may be too crude to account for the diversity in clinical, serological, and electrophysiological findings. A more refined classification of patients may lead to more targeted and individualized therapies.
